Ficerafusp alfa, a bifunctional antibody, targets EGFR and TGF-β, potentially offering anti-tumor activity in HNSCC patients. The FORTIFI-HN01 trial evaluates ficerafusp alfa with Keytruda in ...
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J ...
Patients with head and neck squamous cell carcinoma can talk to their care team about a trial evaluating petosemtamab for recurrent or metastatic disease. The first patient has been dosed in a phase 3 ...
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic ...
Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial. This ...
Neoadjuvant pepinemab treatment shows potential to enhance immune response and improve survival in metastatic melanoma and head and neck cancer. Vaccinex, Inc. announced promising findings regarding ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results